- Opinion
- [Reporter’s View] Additions to the post-management system
- by Eo, Yun-Ho Apr 12, 2024 05:41am
- “The introduction of the post-management system aims to secure additional evidence related to medicines of uncertain safety and efficacy. The system is intended to improve healthcare by reverifying those medicines with medical knowledge.” Although the intention seems reasonable, some are voicing concerns. The concern is that reinforci
- Policy
- Reimb price of Forxiga generics fluctuates amid changes
- by Lee, Tak-Sun Apr 12, 2024 05:41am
- How the changes in reimbursement status of Forxiga (dapagliflozin propanediol monohydrate) generics will affect market competition is gaining industry-wide attention. The generic versions, which had been introduced to the market in April last year, are facing price changes due to changes in their reimbursement status. The premium pricing
- Company
- K-Pharma wins another patent dispute against ‘Entresto’
- by Kim, Jin-Gu Apr 11, 2024 05:45am
- As generic companies win the third trial surrounding the method-of-use patent of Novartis’ ‘Entresto,’ a heart failure treatment, they are one step closer to an early entry of their generic products. Now, the patent hurdle is down to two for early entry of generic versions of Entresto. If generic companies succeed in overcoming the
- Policy
- Clopidogrel recall due to 1 CMO…’no issue escalation’
- by Lee, Hye-Kyung Apr 11, 2024 05:44am
- The issue that stirred up the clopidogrel recall that had been ongoing since March was found to have been caused by a single contract manufacturer, making the concern of it escalating to a series of recalls unlikely. Starting with Daewoong Bio's 'Clovons Tab' on March 17, the Ministry of Food and Drug Safety recalled a total of 29 items f
- Company
- SK’s CMO business posted KRW 812 billion last year…
- by Chon, Seung-Hyun Apr 11, 2024 05:44am
- SK Group's contract manufacturing organization (CMO) business posted a deficit last year. Sales reached nearly KRW 1 trillion, but its growth was sluggish. Investments increased due to the expansion of production facilities at acquired companies, and demand for contract manufacture of COVID-19 drugs from overseas pharmaceutical companies decreas
- Company
- NIP vaccine Vaxneuvance lands in ‘Big 5’ hospitals in KOR
- by Eo, Yun-Ho Apr 11, 2024 05:44am
- The pneumococcal vaccine Vaxneuvance, which can now be received free of charge in Korea, is quickly landing in general hospitals in Korea. According to industry sources, MSD’s vaccine has passed the drug committees (DCs) of the ‘Big 5’ tertiary hospitals in Korea, including Samsung Medical Center, Seoul National University Hospital, Se
- Policy
- 4th-generation, 3 chamber IV nutrition receives reimb
- by Lee, Tak-Sun Apr 11, 2024 05:44am
- Fourth-generation 3 chamber Total Parenteral Nutrition (TPN), with enhanced amino acids contents, are being introduced into the market. Following the reimbursement listing of related products by Baxter and JW Pharmaceutical, HK inno.N and Fresenius Kabi have joined the competition. Companies that competed previously in the third-generat
- Company
- Mundipharma Korea closes its opioid analgesics business
- by Son, Hyung-Min Apr 9, 2024 05:50am
- Mundipharma Korea is drastically reorganizing its opioid analgesics specialty drug business unit. This is the second time the Korean branch made such large-scale reshuffles since the bankruptcy of its US headquarters, Purdue Pharma in August 2022. The company is known to be searching for a domestic pharmaceutical company to take over the sal
- Policy
- Approval of Beyfortus imminent in Korea
- by Lee, Hye-Kyung Apr 9, 2024 05:50am
- Beyfortus (nirsevimab), a long-acting antibody designed to prevent respiratory syncytial virus (RSV) in infants that was jointly developed by Sanofi and AstraZeneca, is soon to receive marketing authorization in Korea. According to the minutes of the Central Pharmaceutical Affairs Council meeting held on March 6, which was released by the
- Company
- Korean and global pharmas in race for lung cancer drugs
- by Son, Hyung-Min Apr 9, 2024 05:50am
- Pharmaceutical and biotechnology companies in South Korea are conducting clinical trials to overcome drug resistance in conventional non-small cell lung cancer (NSCLC) therapy. These companies are developing 4th-generation lung cancer treatments that have proven effective in patients with drug resistance after the use of 1st-to-3rd-generation ta
